Shares of Soleno were halted ahead of the company announcement of FDA approval of VYKATTM XR to treat hyperphagia.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics announces FDA approval of VYKATTM XR to treat hyperphagia
- Soleno Therapeutics trading halted, news pending
- Soleno Therapeutics resumed with a Buy at Stifel
- Optimistic Buy Rating for Soleno Therapeutics Amid Anticipated FDA Approval and Strong Financial Position
- Soleno Therapeutics Reports 2024 Financial Results and Strategic Progress